UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): January 23, 2009
NEKTAR
THERAPEUTICS
(Exact
name of Registrant as specified in its charter)
|
Delaware
|
0-24006
|
94-3134940
|
||
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
201
Industrial Road
San
Carlos, California 94070
(Address
of principal executive offices and Zip Code)
Registrant’s
telephone number, including area code: (650) 631-3100
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
|
Item
5.02
|
Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain
Officers.
|
(b) On January 23, 2009,
Irwin Lerner, a member of our Board of Directors, has decided to retire from the
Board of Directors due to personal reasons. His resignation was effective
as of January 23, 2009. Please refer to Exhibit 99.1.
|
Item
9.01
|
Financial
Statements and Exhibits
|
|
Exhibit Number
|
Description
|
|
|
99.1
|
Press
Release issued on January 29, 2009 by Nektar Therapeutics announcing the
retirement of Irwin Lerner from the Board of
Directors.
|
SIGNATURES
Pursuant
to the requirement of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
By:
|
/s/ Gil M. Labrucherie
|
|
Gil
M. Labrucherie
|
|
|
General
Counsel and Secretary
|
|
| Date: | January 29, 2009 |
EXHIBIT
INDEX
|
Exhibit Number
|
Description
|
|
|
99.1
|
|
Press
Release issued on January 29, 2009 by Nektar Therapeutics announcing the
retirement of Irwin Lerner from the Board of
Directors.
|
News
Release
Nektar
Announces Retirement of Irwin Lerner from Board of Directors
San Carlos, Calif., January 29,
2009 — Nektar Therapeutics (Nasdaq: NKTR) announced today that Irwin
Lerner has retired from its Board of Directors effective January 23,
2009. Mr. Lerner, former Chairman of Hoffmann-La Roche Inc., has been
a member of the Nektar Board of Directors since 1999. He is retiring
due to personal reasons.
The Board
of Directors and the Company wish to acknowledge the contributions that Mr.
Lerner has made by providing the benefit of his extensive industry experience to
Nektar over a near ten-year period.
“It is a
privilege to have worked with Irwin as a colleague and advisor,” said Howard W.
Robin, President and CEO of Nektar and member of the Board of
Directors. “On behalf of the entire Board and the Company, we extend
our deepest appreciation to Irwin for his many years of service to
Nektar.”
About
Nektar
Nektar
Therapeutics is a biopharmaceutical company developing novel therapeutics based
on its advanced polymer conjugation technology platforms. Nektar’s technology
and drug development expertise have enabled nine approved products for partners,
which include leading biopharmaceutical companies. Nektar is also developing a
robust pipeline of its own high-value therapeutics that addresses unmet medical
needs by leveraging and expanding its technology platforms to improve and enable
molecules. More information on Nektar is available at www.nektar.com
Jennifer
Ruddock, 650-631-4954
jruddock@nektar.com
Susan A.
Noonan, 212-966-3650
The SAN
Group
Susan@sanoonan.com
# #
#